{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:18:51Z","timestamp":1792930731251,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcjo.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:04:03Z","timestamp":1779336243000},"page":"665-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetes"],"prefix":"10.1016","volume":"61","author":[{"given":"Tehila","family":"Shlomov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-5157","authenticated-orcid":false,"given":"Itay","family":"Nitzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofira","family":"Zloto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jcjo.2026.01.010_bib0001","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.jcjo.2026.01.010_bib0002","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1210\/clinem\/dgac252","article-title":"Future projections in thyroid eye disease","volume":"107","author":"Barbesino","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.jcjo.2026.01.010_bib0003","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1210\/clinem\/dgac168","article-title":"Teprotumumab and the evolving therapeutic landscape in thyroid eye disease","volume":"107","author":"Kossler","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0004","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0007","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1210\/er.2018-00163","article-title":"Thyroid dysfunction and diabetes mellitus: two closely associated disorders","volume":"40","author":"Biondi","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108270","article-title":"Emerging roles of glucagon-like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities","volume":"239","author":"Shao","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0009","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.clinthera.2017.03.013","article-title":"Treatment strategy for type 2 diabetes with obesity: focus on glucagon-like peptide-1 receptor agonists","volume":"39","author":"Ji","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0010","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171240","article-title":"Glucagon-like peptide 1 receptor agonist use and the effect on diabetic retinopathy: an uncertain relationship","volume":"178","author":"Hui","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0014","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ophtha.2025.02.011","article-title":"Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist","volume":"132","author":"Vasu","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0018","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","article-title":"Reader\u2019s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding","volume":"330","author":"Mamdani","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/IOP.0000000000002770","article-title":"Effect of cannabis usage on thyroid eye disease","volume":"41","author":"Zong","year":"2025","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0020","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0021","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0022","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.3390\/ijms24065714","article-title":"Effects of semaglutide and empagliflozin on inflammatory markers in patients with type 2 diabetes","volume":"24","author":"Reppo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjo.2026.01.010_bib0023","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:38:07Z","timestamp":1781253487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418226000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0008418226000116"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.01.010","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetes","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}